A Systematic Review of ABCB1 Polymorphisms and Antiseizure Medication Resistance: Insights from Effect Size and Study Power Analysis
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26125548 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Aurelija Daškevičiūtė und 6 weiteren Autor:innen. Beteiligte Einrichtung: Clinic of Neurology and Neurosurgery, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, LT-08661 Vilnius, Lithuania. Hauptthemen laut MEDLINE: Polymorphism, Single Nucleotide, Anticonvulsants, Drug Resistance, Epilepsy. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The most investigated ABCB1 single-nucleotide polymorphisms (SNPs) related to antiseizure medication resistance are rs1045642 (c.3435C>T, p.Ile1145=), rs2032582 (c.2677G>T/A, p.Ala893Ser/Thr), and rs1128503 (c.1236C>T, p.Gly412=). We conducted a literature review to evaluate the genotype frequencies of rs1045642, rs2032582, and rs1128503 SNPs in different ancestries among the drug-resistant and drug-responsive epilepsy groups. Furthermore, we performed effect size and study power analyses and determined the expected sample size to reach a study power of 0.8 for each conducted research. High and very high statistical power for the rs1045642, rs2032582, and rs1128503 polymorphisms was achieved in 58.0, 60.7, and 31.8% of the studies, respectively. The effect sizes (ES) of rs1045642, rs2032582, and rs1128503 ranged from 0.03–1.04, 0.06–0.92, and 0.04–0.64, respectively. The required sample sizes for rs1045642, rs2032582, and rs1128503 ranged from 9–13,000, 12–2600, and 24–5700 participants, respectively. None of the polymorphisms showed a statistically significant association with antiseizure medication resistance in the forest plots. Our analysis provides valuable guidance for future genetic association studies in the field of drug-resistant epilepsy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinic of Neurology and Neurosurgery, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, LT-08661 Vilnius, Lithuania.
- Faculty of Medicine, Vilnius University, LT-03101 Vilnius, Lithuania.
- Department of Human and Medical Genetics, Institute of Biomedical Sciences, Faculty of Medicine, Vilnius University, LT-08661 Vilnius, Lithuania.
- Vilnius University Hospital Santaros Clinics, LT-08661 Vilnius, Lithuania.
ORCID-Profile: Edgaras Zaboras
Zitieren
APA
Daškevičiūtė, A., Zaboras, E., Navalinskas, J., Baronas, K., Jasionis, A., Navickienė, E., & Mameniškienė, R. (2025). A Systematic Review of ABCB1 Polymorphisms and Antiseizure Medication Resistance: Insights from Effect Size and Study Power Analysis. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26125548
Vancouver
Daškevičiūtė A, Zaboras E, Navalinskas J, Baronas K, Jasionis A, Navickienė E, et al. A Systematic Review of ABCB1 Polymorphisms and Antiseizure Medication Resistance: Insights from Effect Size and Study Power Analysis. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26125548
BibTeX
@article{Dakeviit2025,
author = {Daškevičiūtė, Aurelija and Zaboras, Edgaras and Navalinskas, Jonas and Baronas, Karolis and Jasionis, Arminas and Navickienė, Eglė and Mameniškienė, Rūta},
title = {A Systematic Review of ABCB1 Polymorphisms and Antiseizure Medication Resistance: Insights from Effect Size and Study Power Analysis},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26125548}
}
EUVIMED